映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

已收盘 11-04 16:08:10

109.100

+7.700

+7.59%

最高109.900	最低100.400	成交量140.19万
今开101.400	昨收101.400	日振幅9.37%
总市值99.34亿	流通市值99.34亿	总股本9,105万
成交额1.48亿	换手率1.54%	流通股本9,105万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":109.1,"timestamp":1793779690007,"preClose":101.4,"halted":0,"volume":1401865,"delay":0,"changeRate":0.07593688362919121,"floatShares":91051100,"shares":91051100,"eps":-46.803011306128525,"marketStatus":"已收盘","change":7.7,"latestTime":"11-04 16:08:10","open":101.4,"high":109.9,"low":100.4,"amount":147824408,"amplitude":0.093688,"askPrice":109.2,"askSize":3400,"bidPrice":109.1,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-18.949503261445397,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":101.4,"openAndCloseTimeList":[[1793755800000,1793764800000],[1793768400000,1793779200000]],"volumeRatio":0.797643,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606/wiki","defaultTab":"wiki","newsList":[{"id":"1168766675","title":"映恩生物-B：朱忠远增持，好仓比例升至17.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168766675","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168766675?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:31","pubTimestamp":1793784694,"startTime":"0","endTime":"0","summary":"朱忠远于2026年11月3日在联交所场内以每股均价101.2425港元买入映恩生物-B（09606）股份3.00万股，涉资约303.73万港元，属场内主动交易，即在二级市场直接买卖股份。朱忠远此次增持前持有映恩生物-B好仓1610.97万，占比17.53%；增持后持股量为1613.97万，好仓比例升至17.56%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680086060","title":"港股异动 | 映恩生物-B(09606)涨近6% 获多名董事及高级管理层作出自愿禁售承诺 Elfe-D有望成为重磅产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2680086060","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680086060?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:45","pubTimestamp":1793771119,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B午后涨近6%，截至发稿，涨5.72%，报107.2港元，成交额7597.65万港元。消息面上，近日，映恩生物-B发布公告称，公司董事及高级管理层对公司长期价值及未来发展前景充满信心。招银国际研报指出，映恩生物-B估值仍主要由B7-H3 ADC资产Elfe-D驱动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","HK0000252152.HKD","BK4588","09606","HK0000500386.USD","HK0000252160.HKD","VXUS","BK1161","LU2543165471.USD","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145237528","title":"异动解读｜映恩生物-B盘中上涨5.03%，主席连续增持提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1145237528","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145237528?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:31","pubTimestamp":1793770301,"startTime":"0","endTime":"0","summary":"11月4日，映恩生物-B盘中上涨5.03%，报106.5港元，成交额7199.42万港元。消息面上，公司董事会主席朱忠远于11月2日在联交所场内以每股103.423港元增持3万股，涉资约310.27万港元，增持后持股升至约1610.97万股，好仓比例由17.49%增至17.53%。此前公司已披露回购进展，累计回购79.42万股、总代价约1.25亿港元，且主席拟进一步增持股份，显示管理层持续释放对公司长期价值的信心信号。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"主席连续增持，映恩生物-B盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680740630","title":"董事会主席朱忠远增持映恩生物-B(09606)3万股 每股作价103.423港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680740630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680740630?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:12","pubTimestamp":1793704331,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，11月2日，董事会主席朱忠远增持映恩生物-B(09606)3万股，每股作价103.423港元，总金额约为310.27万港元。增持后最新持股数目约为1610.97万股，持股比例为17.53%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2543165471.USD","09606","EWH","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179590552","title":"映恩生物-B11月3日回购1.50万股，耗资约150.59万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179590552","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179590552?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:01","pubTimestamp":1793703707,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年11月3日发布公告称，公司当日通过香港联交所场内回购1.50万股股份，占回购前已发行股本约0.016%。本次回购价格介乎每股99.40港元至101.20港元，涉资合计约150.59万港元。完成后，库存股数目由84.77万股增至86.27万股。同日，公司因非发行人董事根据于2021年2月28日采纳并于2023年6月25日修订的首次公开发售前股权激励计划行使购股权，发行普通股9300股，每股发行价9.8066港元。公司确认已遵守香港联交所上市规则及相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B11月3日回购1.50万股，耗资约150.59万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184123044","title":"映恩生物-B：朱忠远增持，好仓比例升至17.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184123044","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184123044?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:32","pubTimestamp":1793698362,"startTime":"0","endTime":"0","summary":"朱忠远于2026年11月2日在联交所场内以每股均价103.4230港元买入映恩生物-B股份3.00万股，涉资约310.27万港元，属场内主动交易，即在二级市场直接买卖股份。朱忠远此次增持前持有映恩生物-B好仓1607.97万，占比17.49%；增持后持股量为1610.97万，好仓比例升至17.53%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121162207","title":"异动解读｜映恩生物-B盘中下跌5.37%，回购与增持难敌临床数据扰动","url":"https://stock-news.laohu8.com/highlight/detail?id=1121162207","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121162207?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:41","pubTimestamp":1793670098,"startTime":"0","endTime":"0","summary":"11月3日，映恩生物-B盘中下跌5.37%，报100.1港元，成交额671.36万港元。消息面上，公司11月2日披露斥资99.21万港元回购1万股，回购股份作为库存股持有；此前10月30日，董事会主席朱忠远在场内增持1万股，持股比例升至17.5%。不过，市场焦点仍集中在DB-1303三期数据扰动。该试验虽达到主要终点，但无进展生存期仅为适度改善，且间质性肺病发生率高于此前研究，资金对疗效与安全性预期仍在重估。公司主营ADC创新药研发。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物盘中下跌，回购增持难敌临床数据扰动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149828334","title":"映恩生物-B于11月2日完成股份回购并发行新股","url":"https://stock-news.laohu8.com/highlight/detail?id=1149828334","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149828334?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:51","pubTimestamp":1793623900,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年11月2日发布公告，披露公司在当日同时进行了股份回购与新股发行，其中回购股份部分作为库存股持有，导致已发行股本构成发生变动。根据公告，映恩生物-B于2026年11月2日通过香港联交所场内回购股份1万股，约占回购前已发行股本的0.011%，每股价格介乎98.55港元至99.60港元，涉资共99.21万港元。回购授权于2026年6月26日获得批准，剩余可回购股份数为9,058,021股，公司自相关授权生效后已合计回购521,400股，占授权当日公司已发行股本约0.5756%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B于11月2日完成股份回购并发行新股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680520917","title":"映恩生物-B(09606)11月2日斥资99.21万港元回购1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680520917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680520917?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:49","pubTimestamp":1793623788,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年11月2日斥资99.21万港元回购1万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","HK0000252160.HKD","09606","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680755723","title":"朱忠远增持映恩生物-B(09606)1万股 每股作价约105.72港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680755723","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680755723?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:06","pubTimestamp":1793617573,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月30日，朱忠远增持映恩生物-B(09606)1万股，每股作价105.7150港元，总金额为105.7150万港元。增持后最新持股数目约为1607.97万股，持股比例为17.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","09606","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126916107","title":"映恩生物-B：朱忠远增持，好仓比例升至17.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126916107","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126916107?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:41","pubTimestamp":1793612493,"startTime":"0","endTime":"0","summary":"朱忠远于2026年10月30日在联交所场内以每股均价105.715港元买入映恩生物-B（09606）股份1.00万股，涉资约105.72万港元，属场内主动交易，即在二级市场直接买卖股份。朱忠远此次增持前持有映恩生物-B好仓1606.97万，占比17.49%；增持后持股量为1607.97万，好仓比例升至17.5%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190906688","title":"映恩生物-B回购43,500股股份，总额约465.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190906688","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190906688?lang=zh_cn&edition=full","pubTime":"2026-10-30 20:26","pubTimestamp":1793363166,"startTime":"0","endTime":"0","summary":"2026年10月30日，映恩生物-B公告称，于当日通过香港联交所场内回购43,500股普通股，占回购前已发行股本约0.048%。每股最高回购价为110.7港元，最低回购价为103.7港元，合计耗资约465.11万港元。本次回购后，库存股数增至837,700股。与此同时，公司于2026年10月29日、30日先后因执行首次公开发售前股权激励计划而发行新股6,600股及9,800股，合计16,400股。本次发行后公司已发行股本增至91,056,597股，合并库存股后，总股本为91,894,297股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B回购43,500股股份，总额约465.11万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679115032","title":"映恩生物-B(09606.HK)10月30日斥资465.11万港元回购4.35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679115032","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679115032?lang=zh_cn&edition=full","pubTime":"2026-10-30 20:24","pubTimestamp":1793363044,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","09606","HK0000500386.USD","BK1161","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121626160","title":"异动解读｜映恩生物-B盘中下跌5.03%，高管禁售承诺后资金仍聚焦临床数据扰动","url":"https://stock-news.laohu8.com/highlight/detail?id=1121626160","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121626160?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:13","pubTimestamp":1793344408,"startTime":"0","endTime":"0","summary":"10月30日，映恩生物-B盘中下跌5.03%，报103.9港元，成交额1.22亿港元。公司此前公告，董事及高级管理层自10月29日至次年4月28日作出六个月自愿禁售承诺，显示对长期价值及发展前景有信心。不过，公司股价近期核心扰动仍来自DB-1303全球3期数据。尽管试验达到主要终点，但无进展生存期仅录得适度改善，且间质性肺病发生率高于此前研究，市场仍在消化疗效与安全性预期落差。近日公司亦持续回购，主席并拟进一步增持，以稳定市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物盘中下跌，临床数据扰动持续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679474816","title":"看好公司发展前景 映恩生物-B(09606)董事及高级管理层作出自愿禁售承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2679474816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679474816?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:03","pubTimestamp":1793268205,"startTime":"0","endTime":"0","summary":"映恩生物-B公布，公司董事及高级管理层对公司长期价值及未来发展前景充满信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","HK0000252152.HKD","HK0000500386.USD","LU2543165471.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102771395","title":"映恩生物-B（09606）高管集体承诺六个月禁售 2026年10月29日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1102771395","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102771395?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:00","pubTimestamp":1793268030,"startTime":"0","endTime":"0","summary":"映恩生物-B10月29日发布自愿公告称，公司董事及高级管理层基于对公司长期价值及未来发展前景的信心，已自愿作出禁售承诺。自2026年10月29日至2027年4月28日，上述人员将不发起或指示任何人出售或以其他方式处置其直接或间接实益拥有的公司股份，包括因行使购股权而获得的任何股份，禁售期为六个月。公司提醒股东及潜在投资者在买卖公司证券时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679042071","title":"招银国际：映恩生物-B(09606.HK)Elfe-D联用数据强化ADC + IO 2.0论点 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2679042071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679042071?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:00","pubTimestamp":1793260806,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","LU2543165471.USD","BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166793189","title":"异动解读｜映恩生物-B盘中上涨5.35%，回购与主席增持计划提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1166793189","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166793189?lang=zh_cn&edition=full","pubTime":"2026-10-29 10:46","pubTimestamp":1793242013,"startTime":"0","endTime":"0","summary":"10月29日，映恩生物-B盘中上涨5.35%，报112.2港元，成交额7208.54万港元。消息面上，公司10月28日披露持续回购进展，并公告董事会主席朱忠远拟进一步增持股份，向市场释放管理层对公司长期价值的积极信号。具体看，公司当日回购15.8万股，耗资约1701.63万港元；截至公告日，累计回购79.42万股，总代价约1.25亿港元。另据披露，朱忠远此前已增持3万股，每股作价约103.22港元，并拟进一步增持不超过500万美元股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物盘中上涨，回购增持提振信心","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678849898","title":"映恩生物－Ｂ：已购回79.42万股股份 董事会主席拟增持不超1000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678849898","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678849898?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:35","pubTimestamp":1793190937,"startTime":"0","endTime":"0","summary":"南财智讯10月28日电，映恩生物－Ｂ（09606.HK）发布自愿公告，公司于2026年股东周年大会上获授新一般授权以购回不超过已发行股份总数10%的股份。截至公告日，公司已合共购回79.42万股股份，总代价约为1.25亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283912437346.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283912437346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000252160.HKD","BK1161","09606","HK0000252152.HKD","HK0000500386.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678460086","title":"映恩生物-B(09606.HK)董事会主席朱忠远拟进一步增持不超过500万美元的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2678460086","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678460086?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:34","pubTimestamp":1793190872,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","HK0000500386.USD","BK1161","HK0000252160.HKD","LU2543165471.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.0461},{"period":"1month","weight":-0.4819},{"period":"3month","weight":-0.4429},{"period":"6month","weight":-0.6097},{"period":"1year","weight":-0.6787},{"period":"ytd","weight":-0.66}],"compareEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0922},{"period":"6month","weight":-0.1164},{"period":"1year","weight":-0.1006},{"period":"ytd","weight":-0.0821}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}